Genmab A/S (Genmab A/S) Sale Of Investment : $1,446 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Sale Of Investment?

Genmab A/S's sale of investment for the three months ended in Dec. 2023 was $312 Mil. It means Genmab A/S gained $312 Mil from selling investments. Genmab A/S's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was $1,446 Mil.

Compared with last quarter ($340 Mil in Sep. 2023 ), Genmab A/S gained less money from selling investments in Dec. 2023 ($312 Mil).

Genmab A/S Sale Of Investment Historical Data

The historical data trend for Genmab A/S's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Sale Of Investment Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sale Of Investment

Get a 7-Day Free Trial

586.06

1,695.72

2,265.16

1,032.91

1,463.25

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sale Of Investment	Get a 7-Day Free Trial															342.31	426.77	367.15	340.31	312.08

Genmab A/S Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,446 Mil.

Genmab A/S Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.